STOCK TITAN

Kymera Therapeutics, Inc. - $KYMR STOCK NEWS

Welcome to our dedicated page for Kymera Therapeutics news (Ticker: $KYMR), a resource for investors and traders seeking the latest updates and insights on Kymera Therapeutics stock.

Kymera Therapeutics, Inc. (NASDAQ: KYMR) is a biotechnology company harnessing the power of targeted protein degradation (TPD) to develop transformative treatments for previously untreatable diseases. Founded in 2016, and headquartered in Watertown, Massachusetts, Kymera is at the forefront of biotechnology, utilizing the body's innate protein recycling machinery to degrade disease-causing proteins rather than merely inhibiting them.

The company's pioneering platform, Pegasus™, leverages proprietary predictive modeling and an integrated degradation approach to address disease targets previously deemed intractable. This novel modality allows Kymera to target and degrade proteins involved in various critical pathways, including those in immunological diseases and oncology. Key drugs in their pipeline include:

  • KT-474: An IRAK4 degrader currently in Phase 2 trials for immuno-inflammatory conditions.
  • KT-333: A STAT3 degrader in Phase 1 trials, targeting hematological malignancies and solid tumors.
  • KT-253: An MDM2 degrader undergoing Phase 1 trials, aimed at cancers with p53 pathway involvement.
  • KT-621: A STAT6 degrader poised to enter Phase 1 trials, showing promising preclinical results for treating TH2-driven diseases like asthma and atopic dermatitis.

Kymera's achievements include successful partnerships with leading pharmaceutical companies such as Sanofi, ongoing collaborations with research institutions, and securing significant financial backing with over $745 million in cash reserves to support operations into 2027. The company's innovative approach and robust pipeline have earned it recognition as one of Boston’s top workplaces.

Kymera continues to make significant strides in drug discovery and development, with a focus on delivering highly effective, convenient oral therapies. Recent updates include positive preclinical and clinical data presentations at major medical conferences, highlighting the potential of their degradation technology to revolutionize treatment paradigms across various diseases.

For more information, visit Kymera Therapeutics or follow them on X (formerly Twitter) and LinkedIn.

Rhea-AI Summary

Kymera Therapeutics presented new clinical data from its ongoing Phase 1 trial of KT-333, a STAT3 degrader, at the EHA Annual Meeting. KT-333 showed promising results in treating various hematological malignancies, including complete responses in two Hodgkin's lymphoma patients. The trial enrolled 47 patients across seven dose levels, achieving up to 95% STAT3 degradation. Notably, KT-333 was well-tolerated, showing mostly minor side effects. The company plans to continue dose escalation and expects to release more data in the second half of 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.53%
Tags
-
Rhea-AI Summary

Kymera Therapeutics presented new clinical data from its ongoing Phase 1 trial of KT-253, an MDM2 degrader, at the ASCO Annual Meeting. Results showed initial clinical proof of concept with efficacy in patients with tumor types such as MCC and AML. KT-253 demonstrated target engagement and upregulation of p53 pathway biomarkers even at low doses. The compound was generally well tolerated without the hematologic adverse events seen with traditional MDM2 inhibitors. The trial continues with more data expected in the second half of 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company specializing in targeted protein degradation (TPD), announced its participation in the Jefferies 2024 Global Healthcare Conference and the Goldman Sachs 45th Annual Global Healthcare Conference. The Jefferies conference will take place in New York on June 5 at 11:30 a.m. ET, while the Goldman Sachs event will be held in Miami on June 11 at 2:40 p.m. ET. Both events will feature live webcasts, accessible through Kymera's website, with replays available post-events.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.1%
Tags
conferences
Rhea-AI Summary

Kymera Therapeutics announced new clinical data for KT-253, an MDM2 degrader, from its ongoing Phase 1 trial. The data will be presented at the ASCO Annual Meeting from May 31 to June 4, 2024.

The study includes 18 patients, indicating promising results in tumor response and a favorable safety profile. Partial and complete responses were observed in patients with Merkel cell carcinoma and acute myeloid leukemia, respectively. KT-253 was well-tolerated, with common adverse events being nausea, fatigue, and headache. Further data will be shared later this year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
conferences clinical trial
-
Rhea-AI Summary

Kymera Therapeutics presented new preclinical data for KT-621, an oral STAT6 degrader, at the ATS Annual Meeting. KT-621 showed comparable or superior activity to dupilumab in asthma models, inhibiting key cytokines and chemokines involved in TH2 inflammation. Additional data were shared at Digestive Disease Week, showing KT-621's effects on esophageal smooth muscle cells related to eosinophilic esophagitis. Phase 1 trials for KT-621 are expected to start in the second half of 2024, with data anticipated by the first half of 2025. KT-621 aims to offer a convenient oral treatment for asthma and other TH2 respiratory diseases, potentially transforming current treatment paradigms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
-
Rhea-AI Summary

Kymera Therapeutics (NASDAQ: KYMR) announced new Phase 1 data for KT-333, a STAT3 degrader, set to be presented at the European Hematology Association (EHA) Annual Meeting from June 13-16, 2024. The data cut-off date was February 6, 2024. The ongoing study involves 39 patients with various hematologic and solid tumors. Key highlights include two complete responses in classic Hodgkin's lymphoma patients, three partial responses in cutaneous T-cell lymphoma patients, and stable disease in four solid tumor patients. KT-333 achieved a maximum degradation of 97.5% in peripheral blood mononuclear cells, showing favorable immunomodulatory responses. The drug was generally well-tolerated, though two dose-limiting toxicities were observed. Kymera plans to share more data in the second half of 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.52%
Tags
conferences clinical trial
Rhea-AI Summary

Kymera Therapeutics, a clinical-stage biopharmaceutical company, will participate in investor conferences in May 2024. They will be attending events like the BofA Securities 2024 Health Care Conference and the TD Cowen 5th Annual Oncology Innovation Virtual Summit. The Company aims to showcase its progress in developing small molecule medicines through targeted protein degradation (TPD).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
conferences
-
Rhea-AI Summary

Kymera Therapeutics, Inc. announced its first quarter 2024 financial results, reporting $745 million in cash. The company is advancing various clinical-stage programs with data expected in 2025. Business updates include expanding the pipeline with a focus on immunology, unveiling oral degrader programs for STAT6 and TYK2, and ongoing Phase 1 studies for MDM2 and STAT3 inhibitors. Kymera remains well-capitalized and has extended its cash runway into 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.17%
Tags
-
Rhea-AI Summary
Kymera Therapeutics, a clinical-stage biopharmaceutical company, will report its first quarter 2024 financial results on May 2, 2024. The company focuses on developing small molecule medicines through targeted protein degradation. Investors can access the conference call via phone or live webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.28%
Tags
conferences earnings
Rhea-AI Summary
Kymera Therapeutics, Inc. presents new preclinical data on KT-333, a First-in-Class STAT3 degrader, at AACR's poster session. Phase 1 dose escalation studies ongoing with more data expected in 2024. Founder Nello Mainolfi discusses drug discovery strategies. KT-333 shows strong anti-tumor activity by inducing a ternary complex between STAT3 and VHL E3 ligase. Phase 1 trials for KT-333 and KT-253 are in progress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.08%
Tags
none

FAQ

What is Kymera Therapeutics' main focus?

Kymera Therapeutics focuses on developing treatments for previously untreatable diseases using targeted protein degradation to eliminate disease-causing proteins.

What is the Pegasus platform?

Pegasus is Kymera's proprietary platform that leverages predictive modeling and integrated degradation technologies to target and degrade intractable disease-causing proteins.

What are some key drugs in Kymera's pipeline?

Key drugs include KT-474 (IRAK4 degrader), KT-333 (STAT3 degrader), KT-253 (MDM2 degrader), and KT-621 (STAT6 degrader).

What diseases is Kymera targeting?

Kymera is targeting a range of diseases including immuno-inflammatory conditions, various forms of cancer, and TH2-mediated diseases like asthma.

What recent achievements has Kymera made?

Recent achievements include positive preclinical and clinical data, significant partnerships, and financial backing to support operations into 2027.

How does Kymera's technology differ from conventional therapies?

Kymera's technology degrades disease-causing proteins rather than merely inhibiting them, offering potentially more effective and lasting treatments.

Who are Kymera's partners?

Kymera has partnered with leading pharmaceutical companies such as Sanofi and collaborates with various research institutions.

Where is Kymera Therapeutics headquartered?

Kymera Therapeutics is headquartered in Watertown, Massachusetts.

How is Kymera funded?

Kymera has over $745 million in cash reserves, supporting operations and research efforts through various financial backings and a recent equity offering.

Where can I find more information about Kymera?

More information can be found on Kymera's website (www.kymeratx.com) and their official social media profiles on X (formerly Twitter) and LinkedIn.

Kymera Therapeutics, Inc.

Nasdaq:KYMR

KYMR Rankings

KYMR Stock Data

1.96B
40.17M
1.27%
112.82%
16.08%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
WATERTOWN